ALCON (ALC) Company Report

Analyst Coverage

Research analysts who have asked questions during ALCON earnings calls.

Anthony Petrone

Mizuho Group

6 questions for ALC

Also covers: ADMA, AXGN, BSX +24 more

Jack Reynolds-Clark

RBC Capital Markets

6 questions for ALC

Also covers: SNN

Ryan Zimmerman

BTIG

6 questions for ALC

Also covers: CARL, GEHC, GKOS +24 more

David Saxon

Needham & Company

5 questions for ALC

Also covers: ALGN, ATEC, AZTA +11 more

Graham Doyle

UBS Group

5 questions for ALC

Also covers: FMS, PHG, SNN

Issie Kirby

Redburn Atlantic

5 questions for ALC

Also covers: COO, DXCM, PODD +1 more

Larry Biegelsen

Wells Fargo & Company

5 questions for ALC

Also covers: ABT, AXNX, BAX +25 more

Patrick Wood

Morgan Stanley

5 questions for ALC

Also covers: BDX, BLCO, BSX +20 more

Veronika Dubajova

Citigroup

5 questions for ALC

Also covers: FMS, GNNDY, PHG +1 more

Jeffrey Johnson

Robert W. Baird & Co. Inc.

4 questions for ALC

Also covers: ALGN, BBNX, COO +11 more

Brett Fishbin

KeyBanc Capital Markets

3 questions for ALC

Also covers: COO, ICUI, INSP +7 more

David Adlington

JPMorgan Chase & Co.

3 questions for ALC

Also covers: FMS, PHG, SNN

Jeff Johnson

Robert W. Baird & Co.

3 questions for ALC

Also covers: ALGN, BBNX, COO +8 more

Steven Lichtman

Oppenheimer & Co. Inc.

3 questions for ALC

Also covers: ANGO, COO, DXCM +12 more

Susannah Ludwig

Bernstein

3 questions for ALC

Also covers: GNNDY

Thomas Stephan

Stifel

3 questions for ALC

Also covers: GKOS, GMED, RXST +2 more

Tom Stephan

Stifel

3 questions for ALC

Also covers: BLCO, OFIX, RXST

Matt Miksic

Barclays Investment Bank

2 questions for ALC

Also covers: ABT, ATEC, BAX +16 more

Michael Sarcone

Jefferies

2 questions for ALC

Also covers: ALGN, AXGN, CTSO +12 more

Richard Felton

Goldman Sachs

2 questions for ALC

Also covers: FMS, PHG, SNN

Chris Pasquale

Nephron Research LLC

1 question for ALC

Also covers: AXGN, BSX, COO +9 more

Christopher Pasquale

Nephron Research

1 question for ALC

Also covers: AXGN, BSX, COO +12 more

Harry Shrives

Citigroup Inc.

1 question for ALC

Julien Ouaddour

Bank of America

1 question for ALC

Also covers: GNNDY, PHG, SHTPY

Kavya Deshpande

UBS

1 question for ALC

Also covers: QGEN

Lawrence Biegelsen

Wells Fargo

1 question for ALC

Also covers: ABT, BAX, BDX +16 more

Young Li

Jefferies

1 question for ALC

Also covers: ARAY, ATEC, BLCO +8 more

Latest news

Recent press releases and 8-K filings for ALC.

Alcon Reports Strong Q4 2025 Results and Provides Positive 2026 Outlook

ALC

Earnings

Guidance Update

Product Launch

Alcon reported Q4 2025 sales of $2.7 billion, an increase of 7% year-over-year, with core diluted earnings of $0.78 per share. The company generated $1.7 billion in free cash flow for the full year 2025.
For 2026, Alcon anticipates top-line growth of 5% to 7% and core diluted EPS growth of 9% to 12%. Core operating margin is expected to improve by approximately 70 to 170 basis points, driven by new efficiency measures targeting $100 million in annualized run rate savings.
Key product launches are driving momentum, including the Unity VCS and CS platforms which contributed to 18% equipment sales growth in Q4. PanOptix Pro has seen strong U.S. adoption , and Tryptyr is tracking ahead of expectations, with peak sales potentially at the higher end of the $250 million-$400 million range. The company also launched TruPlus and TOTAL30 Multifocal for Astigmatism.
Alcon returned $848 million to shareholders in 2025 through share repurchases and dividends, completing its $750 million repurchase program more than two years ahead of schedule.

2 days ago

Transcript

Alcon Reports Strong Q4 2025 Sales and Product Momentum

ALC

Earnings

Product Launch

Guidance Update

Alcon reported Q4 2025 sales of $2.7 billion, an increase of 7% versus the prior year, with the surgical franchise growing 6% and Vision Care growing 7%.
The company highlighted strong momentum from recent product launches, including the Unity platform and PanOptix Pro, and noted that the launch of Tryptyr is tracking ahead of expectations, with peak sales potentially reaching the higher end of the $250 million-$400 million range.
Alcon generated $1.7 billion in free cash flow in 2025 and returned $848 million to shareholders, including completing a $750 million share repurchase program in January 2026, more than two years ahead of schedule.
For 2026, the company anticipates aggregate eye care markets to grow 3%-4%, and expects free cash flow to be similar to 2025.

2 days ago

Transcript

Alcon Reports Strong Q4 2025 Results and Provides 2026 Outlook

ALC

Earnings

Guidance Update

Product Launch

Alcon reported Q4 2025 sales of $2.7 billion, an increase of 7% year-over-year, driven by 18% growth in equipment sales due to the Unity platform and 12% growth in Ocular Health.
For the full year 2025, the company generated $1.7 billion in free cash flow and returned $848 million to shareholders, including $682 million in share repurchases.
Alcon provided 2026 guidance, projecting sales growth of 5% to 7%, core operating margin improvement of 70 to 170 basis points, and core diluted EPS growth of 9% to 12%.
New efficiency measures are expected to yield $100 million in annualized run rate savings, with $50 million anticipated to be realized in 2026.
Product innovation continues with the successful launch of the Unity VCS and CS platforms, strong performance of PanOptix Pro, and upcoming launches including TruPlus and an upgraded Vivity lens.

2 days ago

Transcript

Alcon Posts Q4 Growth, Issues FY26 Guidance Below Estimates

ALC

Earnings

Guidance Update

Revenue Acceleration/Inflection

Alcon reported Q4 2025 revenue of $2.7 billion and full-year 2025 sales of approximately $10.3 billion, with core diluted EPS for FY 2025 rising to $3.07.
Q4 core (adjusted) EPS was $0.78, narrowly missing the consensus of $0.79.
The company issued FY 2026 guidance for adjusted EPS of $3.35–$3.44 and sales of $10.835 billion–$11.041 billion, which are below some street estimates.
Management attributed 2025's performance to new product launches that accelerated sales and expressed optimism for sustainable growth into 2026.
Alcon generated $1.7 billion in free cash flow and returned approximately $848 million to shareholders via buybacks and dividends in 2025.

3 days ago

Morningstar

Alcon Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Outlook

ALC

Earnings

Guidance Update

M&A

Alcon reported fourth-quarter 2025 sales of $2.7 billion, an increase of 9% on a reported basis compared to Q4 2024, with diluted EPS of $0.44 and core diluted EPS of $0.78. Full-year 2025 net sales reached $10.3 billion, up 5% from 2024.
For the full-year 2025, Alcon generated $2.3 billion in cash from operations and $1.7 billion in free cash flow, and returned $848 million to shareholders through share repurchases and dividends.
The company provided a 2026 outlook, projecting net sales growth of +5% to +7% (constant currency), core operating margin change of +70 to +170 basis points, and core diluted EPS growth of +9% to +12% (constant currency).
Alcon highlighted new product launches as a driver for sales acceleration and completed the acquisition of LumiThera in September 2025 and a majority interest in Aurion Biotech in March 2025, expanding its Surgical and Vision Care portfolios.

3 days ago

6-K

Alcon Reports Fourth-Quarter and Full-Year 2025 Financial Results

ALC

Earnings

Guidance Update

Share Buyback

Alcon reported fourth-quarter 2025 sales of $2.7 billion, an increase of 9% on a reported basis, and full-year 2025 sales of $10.3 billion, up 5% compared to the prior year.
Diluted EPS for Q4 2025 was $0.44, with core diluted EPS at $0.78.
For full-year 2025, the company generated $2.3 billion in cash from operations and $1.7 billion in free cash flow.
Alcon returned $848 million to shareholders in full-year 2025 through share repurchases and dividends, and completed its $750 million share repurchase program as of January 20, 2026.
The 2026 outlook projects constant currency net sales growth of +5% to +7% and core diluted EPS growth of +9% to +12%.

3 days ago

Press Release

Alcon Discusses Product Innovation and Market Outlook at J.P. Morgan Healthcare Conference

ALC

Product Launch

New Projects/Investments

Guidance Update

Alcon, an eye care specialist, plans to launch 10 to 15 new products over the next couple of years, including the international rollout of PanOptix Pro in 2026 and the launch of TruePlus in Q2.
The company's new Unity platform is designed to enhance efficiency in cataract surgery, with Unity 4D phaco demonstrating 48% faster performance and 41% less energy delivered compared to existing technology.
Alcon anticipates continued solid market growth of 4%-5% in its surgical business and 4%-6% in vision care, driven by strong underlying demand and new product flow.
Alcon is the largest investor in eye care development, spending approximately $1 billion annually, and expects to expand margins while generating around $2 billion in free cash flow each year, with organic investment as its primary capital allocation focus.

Jan 13, 2026, 4:15 PM

Transcript

Alcon Discusses Innovation, Market Growth, and Financial Outlook at J.P. Morgan Conference

ALC

Product Launch

New Projects/Investments

M&A

Alcon, an eye care specialist, is the largest investor in developing eye care, spending approximately $1 billion annually , and anticipates durable, resilient market growth with underlying demand continuing to run hot.
The company is experiencing a period of unique innovation productivity, planning to launch 10 to 15 new products in the next couple of years. About 10 products introduced last year are expected to have a full-year effect this year, with more coming, leading to a double-digit number of products contributing to growth by next year.
Key product developments include the Unity platform for cataract surgery, which will pilot late this year and launch next year , and the successful launch of TripTier for dry eye, a novel TRPM8 receptor agonist, with full reimbursement anticipated by mid-next year.
Alcon expects to generate around $2 billion in free cash flow annually and historically achieves 150-200 basis points of margin expansion. However, approximately 40 basis points of pressure on margins is expected next year due to Aurion investment and $50-$100 million in tariff pressure.
The company's M&A strategy focuses on acquiring single-product companies that struggle to scale, leveraging Alcon's global footprint, as seen in the recent, though unsuccessful, attempt to acquire Star.

Jan 13, 2026, 4:15 PM

Transcript

Alcon Discusses Product Innovation, Market Conditions, and Financial Outlook at J.P. Morgan Conference

ALC

Product Launch

New Projects/Investments

M&A

Alcon is driving growth with significant product innovation, including the UNITY 4D Phaco system, which is 48% faster than previous technology, and upgraded PanOptix IOLs set for international launch in 2026. New products like TRUEplus Monofocal Plus (Q2 2026) and TOTAL30 Multifocal Toric contact lenses (Q1 2026) are also being introduced.
The company expects to introduce a double-digit number of products contributing to growth by next year, with approximately 10 products from last year having a full-year effect in the current year.
For the upcoming year (2026), Alcon anticipates approximately 40 basis points of margin pressure due to investments in Aurion and $50 million-$100 million in tariff pressure, while historically maintaining 150-200 basis points of margin expansion.
Alcon projects annual free cash flow of around $2 billion and maintains a disciplined capital allocation strategy, prioritizing organic investment and evaluating M&A opportunities, as demonstrated by its decision not to proceed with the STAAR acquisition.

Jan 13, 2026, 4:15 PM

Transcript

ALC: Intraocular Lens Market Projected to Reach USD 9.85 Billion by 2033

ALC

M&A

Product Launch

The global Intraocular Lens Market was valued at USD 5.97 billion in 2025 and is projected to reach USD 9.85 billion by 2033, growing at a CAGR of 6.48% during the forecast period of 2026–2033.
The U.S. Intraocular Lens Market was valued at USD 1.60 billion in 2025 and is expected to reach USD 2.59 billion by 2033, expanding at a CAGR of 6.20% over the forecast period of 2026–2033.
Market growth is primarily driven by the rising global geriatric population, increasing incidence of age-related cataracts, and technological advancements, while high costs and limited reimbursement coverage restrict broader market penetration.
In 2025, North America dominated the Intraocular Lens Market, accounting for 38.61% of revenue share, and Asia Pacific is expected to witness the fastest growth with a projected CAGR of 7.03% from 2026-2033.
Recent developments include Alcon's acquisition of STAAR Surgical Company in August 2025 and Johnson & Johnson Vision's launch of the TECNIS PureSee™ intraocular lens in India in February 2025.